It has been an eventful week for Britain’s National Health Service, the socialized-medicine program marking its 75th birthday at perhaps its darkest hour.
On Thursday, around 46,000 doctors staged the latest in a series of walkouts over pay and working conditions, once again putting a spotlight on a service that is chronically understaffed and underfunded. The strike hit just days after another event, albeit less publicized, brought additional attention to the healthcare debate: Fremman Capital, a London-based private equity firm, acquired Medinet, an agency that seeks to tackle acute NHS staffing shortages by hiring NHS doctors and nurses outside their contracted hours.
The crisis, and the coinciding deal, together are revealing of both a health service that is struggling and the opportunities available to PE-backed healthcare companies that have become enmeshed in the nation’s socialized medicine system in recent years.
While the inefficient health service is an attractive target for private investors, the NHS crisis may heighten risk of backlash against PE involvement at a time when the public is demanding more accountability for a broken system.
This article appeared as part of The Weekend Pitch newsletter. Subscribe to the newsletter here.
Public spending for the NHS—which comes via tax revenue and national insurance contributions—has been on the rise in recent years. NHS England’s figures put its 2023-2024 spending at about £157 billion ($205.7 billion), an increase of 1.5% from the previous year. Even so, the service remains chronically underfunded and short-staffed, facing ever-greater pressure from an aging population and the increasing prevalence of chronic diseases.
The result is an NHS increasingly dependent on third-party providers from the private sector, some of which are PE-backed.
PE investment in the nation’s healthcare system has consistently risen every year since 2016 in both deal count and total capital, reaching £15.4 billion across 155 deals, according to PitchBook data. While the deal pace has slowed down this year, there has still been £7.7 billion invested across 51 deals so far.
Many of the investments are in companies offering services to the NHS—most recently Fremmen’s acquisition of Medinet. Some of these investments seek to capitalize on addressing NHS inefficiencies and backlogs that have grown over the years, and made worse by the pandemic. In April 2022, Summit Partners bought 18 Week Support, a London-based group that, like Medinet, offers NHS insourcing. Then there have been investments like PHL Group, acquired by Ethos Capital last September, which provides urgent care and waitlist management services for the NHS and private health providers.
Other investments aim to offer the NHS ancillary services and technology. One is Convenet, an application for managing patient data that got backing from BGF and others in September. Public View, a company that provides benchmarking services, is backed by BCN Group and Beech Tree Private Equity. Investments like these are expected to increase as the NHS pursues more tech-driven efficiencies.
The sacred cow
While PE-backed companies are addressing a clear need in the health system, there is no clear consensus on the extent to which the private sector should get involved.
Many Britons regard the NHS as a national treasure—its founding was even celebrated during the 2012 London Olympics’ opening ceremony. It has become a sacred cow, to the extent that any hint of privatization invariably sparks opposition and significant scrutiny. Any upside that comes with plugging gaps in the system will be tempered by a degree of reputational risk.
Investors in UK nursing homes have already learned this lesson. Two notable examples were operators Southern Cross and Four Seasons Healthcare, both of which collapsed following a period of PE ownership. Both cases left many vulnerable residents of the nursing homes facing uncertainty while former investors were hit with tough questions from regulators and the media.
Southern Cross had been acquired by Blackstone in 2004 and was one of the country’s largest operators when it went public in 2006. However, when it collapsed in 2011, Blackstone received criticism for selling off its real estate portfolio and tying the company into long-term rent commitments. Similarly, Four Seasons shed its real estate assets under successive PE owners before ultimately being bought in 2012 by London-based firm Terra Firma. In 2019, the company went into bankruptcy proceedings after buckling under the weight of its debt.
To be sure, these two high-profile examples don’t necessarily bear comparison to all PE investments in UK healthcare. But they have led to greater public examination of the impact of private equity ownership. They also illustrate the public relations pitfalls that emerge when real-life human costs are factored into financial missteps.
Even with these risks, PE investment in British healthcare will grow as the country’s needs continue to extend beyond what the NHS can provide. The opportunity will likely come via two routes. First, there will be growing demand for companies looking to solve inefficiencies within the current system. Moreover, there will be growth in the private health sector more broadly as more Britons, unhappy with their national medical plan, look for alternatives.
Related read: PitchBook’s Q1 2023 Healthcare Services Report
Featured image by Julia Midkiff/PitchBook News
Learn about our editorial standards.